Follow-On Biologics Get Their Vehicle As Senate Schedules Mark-Up For June 13
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Kennedy pledges to include language in conference report on FDA bill.
You may also be interested in...
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Biocon will manufacture biogeneric of Amgen’s Neupogen for Abraxis, the firm tells “The Pink Sheet” DAILY.
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Biocon will manufacture biogeneric of Amgen’s Neupogen for Abraxis, the firm tells “The Pink Sheet” DAILY.